ONCT (Oncternal Therapeutics Inc) נכסי מאזן של החברה

Oncternal Therapeutics (ONCT) is striving for the global expansion of its tumor-fighting antibody portfolio. However, the business has faced a crisis, shuttering core research due to the dominance of more potent drugs. The asset's market dynamics reflect total assets at 29.40, which is critical for the developer of prostate and blood cancer treatments that holds exclusive pricing power under orphan drug status.

Total assets represent the sum of all organizational resources and liabilities, with the aggregate asset value calculated reversely via ROA to eliminate time lags between reporting periods. This indicator's trend reflects the ability of Oncternal Therapeutics (ONCT) to accumulate capital to overcome stringent FDA regulatory barriers and fund costly clinical trials for targeted blood cancer drugs.